Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-10-31

Study Completion Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients.

The purpose of the phase 2 portion of the study is to determine the antitumor activity of the S-1 and cisplatin regimen established from phase 1 in patients with advanced gastric cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety and Efficacy Study in Patients With Gastric Cancer

NCT00400179

Gastric Cancer

COMPLETED PHASE3

S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis

NCT02291211

Stage IV Gastric Cancer

UNKNOWN PHASE2

Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer

NCT01747707

Gastric Cancer Gastroesophageal Junction Cancer

UNKNOWN PHASE2

S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

NCT01824459

Gastric Cancer

COMPLETED PHASE3

A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer

NCT00142350

Gastric Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

S-1 is an oral fluoropyrimidine which combines tegafur (a 5-FU prodrug) with two classes of modulators which:

* inhibit dihydropyrimidine dehydrogenase (DPD) and
* block phosphorylation of 5-FU in gastrointestinal tissues.

S-1 is designed to enhance the the clinical utility of an oral fluoropyrimidine while ameliorating the disadvantage of gastrointestinal toxicity.

5-Fu and cisplatin have been used as a standard treatment in gastric cancer and preliminary data indicate that S-1 plus cisplatin may result in superior tolerability and efficacy in advanced gastric cancer.

S-1 is currently approved in Japan for treatment of gastric cancer and head and neck cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

S-1

Intervention Type DRUG

cisplatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction
* Has advanced, unresectable cancer at the time of study entry
* Has measurable disease as defined by RECIST criteria, i.e., lesions that can be accurately measured in at least one dimension with the longest diameter ≥20 mm using conventional techniques or ≥10 mm using spiral CT scan
* Is at least 3 weeks post-gastrectomy surgery
* Has not received prior chemotherapy for their cancer (adjuvant therapy is permitted and does not count as prior chemotherapy).
* Has performance status of ≥ 70% on the Karnofsky scale (Appendix B)
* Has a predicted life expectancy of ≥ 12 weeks
* Has an absolute granulocyte count of ≥ 1,500/mm3
* Has a platelet count ≥ 100,000/mm3
* Has a hemoglobin of ≥ 9.0 g/dL
* Has a bilirubin of ≤ 1.5 times the ULN
* Has transaminases ≤ 2.5 times the ULN except for patients with liver metastasis who may have transaminases ≤ 5 times the ULN
* Has a creatinine ≤ ULN and calculated creatinine ≥ 60 mL/min
* According to the judgment of the Investigator, the patient has recovered from all previous anti-cancer treatment-related toxicities to at least Grade 1 (see exceptions above)
* Has stopped all previous investigational drugs at least 4 weeks prior to treatment with S-1 and cisplatin.
* Is able to take medications orally
* Female patients of childbearing potential who are not pregnant and who use acceptable means of contraception while on study and for an additional 30 days after the last dose of study medication. Male patients must use adequate contraception.

Exclusion Criteria

* Has relapsed within 6 months from the end of adjuvant therapy
* Has known brain or leptomeningeal metastases.
* Has any other serious illness or medical condition(s) including, but not limited to, the following:

* uncontrolled congestive heart failure, angina pectoris, arrhythmias, or hypertension ; or any significant medical condition that is a contraindication for chemotherapy
* concurrent malignancy other than gastric cancer except adequately treated carcinoma-in-situ of the cervix or non-melanoma skin cancer
* active infection
* gastrointestinal disorder, including malabsorption, chronic nausea and vomiting, chronic diarrhea
* unstable diabetes mellitus
* psychiatric disorder that may interfere with consent and/or protocol compliance
* known neuropathy (including hearing loss) at baseline of Grade 2 or higher (as per NCI CTC v2.0 see Appendix A)
* Has known hypersensitivity to any of the constituents of the study medication
* Is receiving a concomitant treatment with drugs interacting with S-1.
* Is a pregnant or lactating female or who refuses to use an acceptable means of contraception. Is a male and refuses to use an acceptable means of contraception.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No